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esponsibility of InstAbstract A highly rapid and sensitive liquid chromatographic–electrospray ionization tandem mass
spectrometric (LC–ESI-MS/MS) method was developed and validated for the determination of trans-δ-
viniferin (Rs-1) in rat plasma, urine and feces. All biological samples were prepared by liquid–liquid
extraction and hesperetin was included as an internal standard (IS). Chromatographic separation was
achieved on a shim-pack XR-ODS column using a gradient mobile phase. MS/MS detection was
performed by negative ion electrospray ionization. The method was sensitive with a lower limit of
quantiﬁcation of 1.42 ng/mL and linear over the range of 1.42–2172 ng/mL in all matrices. The method
was applied to study the pharmacokinetics, bioavailability, metabolism, and excretion of Rs-1 in rats
following a single oral or intravenous dose. Two metabolites, Rs-1 glucuronide and Rs-1 sulfate, were
detected in plasma and in urine after administration of Rs-1. The absolute oral bioavailability of Rs-1 was
2.3%, and the total absorption rose to 31.5% with addition of its glucuronide and sulfate metabolites. Only
0.09% of the gavaged dose, including Rs-1 and metabolites, was excreted in the urine, while 60.3% was
found in the feces in unchanged form. The results indicate that both poor absorption and extensive
metabolism were the important factors that led to the poor bioavailability of Rs-1, which can provide a
basis for further studies on structural modiﬁcation and dosage form design.
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Ping Mao et al.2441. Introduction
Resveratrol (trans-3,5,40-trihydroxystilbene) and its oligomers,
including their glucosides, are widely distributed in families, such
as Dipterocarpaceae, Vitaceae, Cyperaceae, Leguminosae and
Gnetaceae. Monomeric resveratrol displays a broad range of
pharmacological activities including cardioprotection, antioxida-
tion, protection against brain damage and prevention against
cancers1–4. Resveratrol can be polymerized into resveratrol oligo-
mers (so-called viniferins) in fungi or plants5–9 and those
resveratrol oligomers have more extensive pharmacological activ-
ities, such as anti-HIV and antitumor effects10–13. However, as
with resveratrol and other stilbenes, the pharmacokinetic properties
of those compounds are not favorable due to their poor bioavai-
lability, extensive metabolism and rapid elimination14,15.
Trans-δ-viniferin (Rs-1, Fig. 1), a resveratrol-trans-dehydrodi-
mer, was ﬁrst found in grapevine (Vitis vinifera L.) in 197716, and
many studies have demonstrated that Rs-1 has numerous pharma-
cological properties, such as anti-inﬂammation6,17, antimicrobial
action18,19, antioxidation7, cardioprotection8 and antidiabetes20.
It has been shown that resveratrol has high absorption but very
low bioavailability after oral administration in humans. At least
70% of oral dose was absorbed based on the urinary excretion
data, and the relatively poor bioavailability was mainly owing to
rapid metabolism14. A previous study has shown that the
bioavailability of Rs-1 in rats was low21, but whether poor
absorption or rapid metabolism or both were responsible for the
poor bioavailability was not determined. The bioavailability,
metabolism and excretion of Rs-1 were investigated in the present
study. A highly rapid and sensitive LC–MS/MS method was
developed and validated for the determination of Rs-1 in rat
plasma, urine and feces. This method yielded shorter sample
turnover rate per sample and higher sensitivity compared with a
previous study21. The method was applied to the assessment of the
pharmacokinetics, bioavailability, metabolism and excretion of
Rs-1 in healthy rats, and LC–MS/MS was used to identify Rs-1
metabolites.2. Materials and methods
2.1. Materials and reagents
Rs-1 (purity 498%) was provided by the Institute of Materia
Medica, Chinese Academy of Medical Sciences (Beijing, China).
Hesperetin (Fig. 1), the internal standard (IS), was purchased from
Sigma (St. Louis, MO, USA). Acetonitrile and methanol were
purchased from ANPEL (Shanghai, China) and acetic acid was
from OE Scientiﬁc Inc. (Newark, NJ, USA). All solvents were
HPLC grade. Other chemicals used were analytical grade and
obtained from Sigma–Aldrich (St. Louis, MO, USA). Water used
in this study was prepared in a Milli-Q water puriﬁcation system
(Billerica, MA, USA).Figure 1 Chemical structures of Rs-1 and hesperetin (IS).2.2. Liquid chromatography and tandem mass spectrometry
conditions
Chromatographic separations were performed on a Shimadzu
UFLC-20AD XR system (Shimadzu, Tokyo, Japan) with a shim-
pack XR-ODS column (75 mm 3 mm, 2.2 μm, Shimadzu,
Tokyo, Japan) maintained at a temperature of 40 1C and a ﬂow
rate of 0.3 mL/min. The mobile phase was composed of A (0.1%
formic acid–water, v/v) and B (0.1% formic acid–acetonitrile, v/v).
A gradient elution program was as follow: 0–0.3 min, 45%–75%
B; 0.3–1.8 min, 75% B; 1.8–2.1 min, 75%–45% B; 2.1–4 min,
45% B. The injection volume was 10 μL.
The Shimadzu UFLC-20AD XR system was coupled on-line to
an Applied Biosystems Sciex Qtrap 5500 (MDS-Sciex, Concord,
Canada) with an electrospray ionization (ESI) interface. The mass
spectrometry was carried out using multiple reaction monitoring
(MRM) and operated by electrospray ionization in negative mode
for Rs-1 and IS. Transitions of precursor-product ion were
monitored at m/z 453.2-411.2 for Rs-1 with a declustering
potential (DP) of –178 V, collision energy (CE) of –35 V, and
m/z 301.1-163.9 for IS with a DP of –100 V, CE of –32 V. Their
collision exit potential (CXP) and entrance potential (EP) were
both –10 V. The source parameters were optimized as follows: ion
spray voltage, –4500 V; temperature, 550 1C; curtain gas (nitro-
gen), 28 psi; nebulizer and turbo gases (nitrogen), 50 and 50 psi,
respectively. MRM transition was monitored with a dwell time of
200 ms. Quantiﬁcation was determined from the peak area ratio of
Rs-1 to IS. Analyst 1.6 software was used for control of
equipment, data acquisition and analysis. The full scan product
mass spectra of Rs-1 and IS are shown in Fig. 2.
2.3. Preparation of stock and working solutions
Stock solutions of Rs-1 and hesperetin (IS) at 0.2 mg/mL were
prepared by dissolving the proper amount of the accurately
weighed reference material in methanol. A series of working
solutions for calibration standards (CS) in a concentration range of
14.2–21,720 ng/mL and quality control (QC) at 14.2, 35.6, 3480
and 17,380 ng/mL were prepared by subsequently diluting Rs-1
stock solution with methanol. The IS working solution at
200 ng/mL was prepared by diluting IS stock solution with
methanol. All of the solutions were stored at –20 1C.
2.4. Preparation of standard and quality control samples
CS and QC samples of Rs-1 were prepared freshly by spiking the
appropriate amount of the working solution into 100 μL of blank
plasma, urine, feces suspension (1 g feces was homogenized with
20 mL of saline for 2 min). CS samples were prepared at
9 concentrations of 1.42–2172 ng/mL and QC samples were at
4 levels of 1.42 (lower limit of quantiﬁcation QC), 3.56 (low QC),
348 (middle QC) and 1738 (high QC) ng/mL.
2.5. Sample preparation
A liquid–liquid extraction (LLE) method was used to extract the
analyte from biological samples (plasma, urine and feces). For
Rs-1 analysis, an aliquot of 100 μL of each plasma, urine or feces
suspension sample was mixed with 20 μL of IS working solution
and the mixture was vortex-mixed for 30 s. For Rs-1 in plasma and
urine, 600 μL ethyl acetate was added, and in feces, 600 μL diethyl
Figure 2 Product ion spectra (MS/MS) of (A) Rs-1 and (B) hesperetin (IS).
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at 12,000 rpm for 10 min at 4 1C, the supernatant fraction was
transferred to a new tube and evaporated to dryness under a gentle
nitrogen stream at 40 1C. The residue was reconstituted in 200 μL
methanol, vortex-mixed for 3 min and subjected to centrifugation
at 12,000 rpm for 10 min at 4 1C. The supernate was injected for
LC–MS/MS analysis. To avoid photochemical isomerization of
Rs-1 to the cis form all laboratory procedures were performed in
dim light.
2.6. Hydrolysis of Rs-1 glucuronide and sulfate with β-
glucuronidase and sulfatase
For quantiﬁcation of Rs-1 glucuronide metabolites and sulfate
metabolites, plasma samples and urine samples were incubated with
β-glucuronidase (Type B-1, Sigma–Aldrich) or sulfatase (Type VIII,
Sigma–Aldrich). The content difference of Rs-1 between samples
with and without enzymolysis was used to calculate the concentration
of Rs-1 glucuronide or sulfate. For Rs-1 glucuronide analysis, 5000 U
of enzyme dissolved in 20 μL of enzyme buffer (0.17 mol/L
ammonium acetate, pH 5.0) was added to 10 μL plasma or 20 μL
urine. The mixture was vortex-mixed for 30 s and incubated with
agitation at 37 1C for 2 h. For sulfate metabolites of Rs-1, 10 μL of
plasma or 20 μL of urine was incubated with 20 U of sulfatase
dissolved in 40 μL of the above enzyme buffer. The plasma samples
were incubated with agitation at 37 1C for 36 h, while the urine
samples for 12 h. After incubation, 90 μL of blank plasma or 80 μL
of blank urine was added to the corresponding samples before
analysis. The following procedures were carried out to determine Rs-
1, as described in Section 2.5.
2.7. Method validation
The extraction methods were validated according to the Guidance
for Industry, Bioanalytical Method Validation of the Food and
Drug Administration (US FDA)22 and European Medical Agency
(EMA) guidelines23 of bioanalytical method validation.
Selectivity was investigated by analyzing blank plasma samples,
urine, and feces from 6 individual rats that were not administered Rs-1
and comparing with the corresponding spiked biological matrices at the
lower limit of quantiﬁcation (LLOQ) level or the samples collected
after intravenous or oral administration of Rs-1. There should be nointerference from the endogenous substances at the retention times of
both Rs-1 and IS using the proposed pretreatment procedure and LC–
MS/MS conditions.
The calibration curve was acquired by comparing the peak area
ratio of analyte to IS (Y) to the nominal analyte concentration (X)
by weighted least-squares linear regression (1/X2 as a weighting
factor). The LLOQ was deﬁned as the lowest concentration of the
calibration curve with S/N ratio greater than 10 and acceptable
accuracy (RE, %; 720%) and precision (RSD, %; r20).
Accuracy and precision were determined in all matrices at QC
concentrations (LLOQ QC, LQC, MQC and HQC; n¼5 each)
using different analytical batches on the same day and on
3 consecutive days. The acceptance criteria for intra- and inter-
day precision (RSD, %) was required to be r15% except for
LLOQ, whose precision should be r20%, and accuracy (RE, %)
was limited to 715% except for LLOQ (720%).
Extraction recovery was determined by comparing peak area of Rs-
1-spiked blank matrix (plasma, urine or feces) with those obtained from
the analyte spiked in post-extracted matrix supernate. The matrix effect
was evaluated by comparing the peak areas of post-extraction matrix
supernate spiked with the analyte versus the standard solution of the
analyte at corresponding concentrations. The extraction recovery and
matrix effect were evaluated at 4 QC concentrations (n¼5). IS
(200 ng/mL) was also investigated similarly.
Stability was examined in all matrices at 4 QC concentrations
(n¼5) under different conditions: at room temperature (2573 1C) for
24 h (short-term stability); through three freeze–thaw cycles; stored at
–80 1C for 20 days (long-term stability); and ready-to-inject samples
placed in an autosampler at room temperature for 24 h (post-
preparative stability). The analyte was considered stable in the
biological matrix when 85%–115% of the initial concentrations
were found.
The Rs-1 concentrations of some plasma, urine and feces
samples exceeded the upper limit of quantiﬁcation (ULOQ). In
the dilution integrity experiment, the accuracy and precision of QC
samples (n¼5 each) diluted from a high concentration were
assessed to investigate the effect of diluting over-range samples
into the linear range with blank matrix.
To evaluate the impact of incubation with β-glucuronidase and
sulfatase on the determination of Rs-1, 4 levels of QC samples of
Rs-1 in plasma and urine were processed by enzymatic hydrolysis
identically to test samples. The requirement for accuracy (RE, %)
was within 715% compared to the nominal concentration.
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2.8.1. Dosing formulations
The suspension formulation for oral dosing was prepared by suspend-
ing an appropriate amount of Rs-1 in a vehicle of 0.5% (w/v) sodium
carboxymethyl cellulose (CMC-Na). The suspension was prepared
freshly and shaken vigorously before oral gavage, and a dosing volume
of 10 mL/kg body weight was used for gavage administration. For
intravenous injection, the solution was prepared freshly by dissolving
Rs-1 in a vehicle of dimethyl sulfoxide (DMSO):polyethylene glycol
(PEG-300):physiological saline (5:50:45, v/v/v) and a dosing volume of
5 mL/kg body weight was used for intravenous injection.
2.8.2. Animals and animal husbandry
The pharmacokinetic study was carried out in healthy male and
female Wistar rats (body weight 200720 g, 8 weeks) obtained from
Beijing Military Medical Sciences Experimental Animal Co., Ltd.
(Beijing, China). All animals were kept in an environmentally
controlled room which was maintained at a temperature of
2472 1C with a relative humidity of 55710% and an approximately
12 h light/dark cycle. All rats had free access to water and food.
2.8.3. Bioavailability study
Twelve rats (6 female and 6 male) were used for the bioavailability
study and were kept in a fasting state with free access to water for 12 h
prior to the experiment. All rats were randomly divided into two groups
(n¼6 per group) for oral and intravenous administration. Rats in groups
1 were administered a single dose of Rs-1 suspension at the dose of
70 mg/kg and serial blood samples (0.4 mL) were collected from the
ocular vein into 1.5 mL Eppendorf tubes at 0.167, 0.5, 1, 1.25, 1.5, 1.75,
2, 2.5, 3.5, 4.5, 6, 8, 12 and 24 h. Rats in group 2 received a single
intravenous administration of Rs-1 solution at a dose of 1.37 mg/kg via
tail vein and blood samples were collected at 0.033, 0.083, 0.167, 0.33,
0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 12 and 24 h after administration. Plasma
samples were collected by centrifugation of collected blood immediately
at 4000 rpm for 10 min at 4 1C and stored at 80 1C until analysis.
2.8.4. Excretion study
An excretion study was carried out in 6 fasted Wistar rats (3 female
and 3 male). The rats were housed in separate metabolic cages after
receiving a single oral dose of Rs-1 suspension at 70 mg/kg. Urine
and feces samples were collected at 0–4, 4–8, 8–12, 12–24, 24–36,
36–48 and 48–60 h. The weight of feces and the volume of the
urine samples were measured, after which all the samples were stored
at –80 1C. Feces samples were individually homogenized in saline
(1 g/20 mL) for 2 min to prepare the suspension for analysis.
2.9. Data analysis
The pharmacokinetic parameters, including the area under the
plasma concentration–time curve from time zero to the last
measurable plasma concentration point (AUC0 t), the area under
the blood concentration–time curve from time zero to inﬁnity
(AUC01), clearance (CL/F), volume of distribution (V/F), mean
residence time (MRT), elimination half-life (t1/2), maximum
concentration (Cmax) and time of reaching Cmax (Tmax) were
evaluated by non-compartmental modeling using DAS Software
(version 3.2.4, China State Drug Administration). The absolute
oral bioavailability (F, %) in rats was calculated according
to the following equation: F (%) ¼ (AUCp.o.Dosei.v.)/
(AUCi.v.Dosep.o.) 100.3. Results and discussion
3.1. Optimization of LC–MS/MS conditions
During method development different mobile phase compositions
(methanol–water and acetonitrile–water) with different buffers such
as ammonium formate and formic acid were investigated to obtain
chromatograms with good resolution and symmetric peak shapes. It
was found that acetonitrile and water containing 0.1% formic acid
could enhance the sensitivity of detection of both Rs-1 and IS. The
elution gradient was also optimized to reduce a matrix effect and
improve peak symmetry. As a result, a chromatogram of good peak
shape and resolution was obtained on a shim-pack XR-ODS column
(75 mm 3 mm, 2.2 μm, Shimadzu, Tokyo, Japan) using gradient
mobile phase with acetonitrile (0.1% formic acid)–water (0.1% formic
acid) in the gradient as described above, and the gradient mode was
shown to be stable according to the method validation procedure.
To obtain better responses the MS conditions were optimized. The
effect of positive and negative ionization modes (ESI) on the
sensitivity of the analysis was investigated. The mass spectral
response and signal stability of Rs-1 and IS (hesperetin) in negative
mode was higher, and the MRM transitions were at m/z 453.2-
411.2 for Rs-1 and m/z 301.1-163.9 for IS. The parameters of
ionization DP, CE, EP, CXP and TEM were also optimized.
3.2. Sample preparation
Extraction methods with protein precipitation or LLE were
investigated to remove interfering compounds from the samples.
Organic solvents, such as methanol, ethanol, acetonitrile and
acetone, were compared in developing the protein precipitation
procedure along with the evaluations for matrix effect, recovery
efﬁciency and reproducibility, but a serious ion suppression or
matrix effect for analyte was observed in the LC–MS/MS analyses
both for Rs-1 and IS, and could not meet the requirements of the
pharmacokinetic study. Ethyl acetate, cyclohexane, n-hexane and
diethyl ether were compared as LLE solvent, and ethyl acetate was
found to be efﬁcient in terms of low matrix effect, high recovery
rate and good repeatability both for Rs-1 and IS except in feces
samples, in which the optimal solvent was diethyl ether. Methanol
and acetonitrile as the solvent to reconstitute biological samples
after evaporation were also compared. It was found that tailing of
peaks particularly of Rs-1 could occur when acetonitrile was used,
and it was much better when methanol was used.
3.3. Optimization of enzymatic hydrolysis conditions
As the reference substances of Rs-1 glucuronide and sulfate
standards were not available, Cmax plasma and urine in the pretest
of Rs-1 oral administration were used as substrates to optimize
enzymatic hydrolysis conditions. The effect of different time and
amount of the enzyme was optimized according to the response
values of Rs-1. When 100 mL plasma or urine were used as
substrate, it was difﬁcult to reach equilibrium, with even 10,000 U
β-glucuronidase or 100 U sulfatase being insufﬁcient after 48 h. In
order to reduce the amount of enzyme and plasma, 10 mL plasma
or 20 mL urine were used to assay the Rs-1 glucuronide and sulfate
conjugates. For β-glucuronidase, the amount of 1000, 2000, 3000,
5000 U and the incubation time of 1, 2 and 3 h were compared. It
was found that after incubation at 37 1C for 2 h, Rs-1 glucuronide
in 10 mL plasma or 20 mL urine with 2000 U β-glucuronidase can
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the amount of 5, 10, 20, 40 U and the incubation time of 2, 4, 12,
24, 36, 48 h were compared. It was found that 20 U sulfatase was
sufﬁcient. Accordingly, 36 and 12 h were the appropriate time to
incubate for plasma and urine samples, respectively.
3.4. Method validation
The developed method was selective as no signiﬁcant endogenous
interference from plasma was observed at the retention times of Rs-1
and IS (Fig. 3) in chromatograms derived from processed blank
samples from 6 different rats, as well as in urine (Fig. 4) and feces
samples (Fig. 5).
All calibration curves showed good linearity over the concentra-
tion ranges of 1.42–2172 ng/mL. The regression equations were as
follows: plasma, Y¼0.00239Xþ0.000922 (R¼0.9991); urine,
Y¼0.00203Xþ0.00112 (R¼0.9995); feces, Y¼0.00305Xþ
0.00155 (R¼0.9994). The LLOQ of Rs-1 was 1.42 ng/mL for all
matrices.
The intra-day and inter-day precision and accuracy data of Rs-1 in
biological matrices are presented in Table 1. The intra-day and inter-
day precision (RSD, %) values were both r10.9%, while the intra-
day and inter-day accuracy (RE, %) were in the range of –3.7% to
2.3% and –2.2% to 1.5%, respectively. The results revealed that all
values were in the acceptable ranges, indicating the method was
reliable and reproducible for the determination of Rs-1 in plasma, urine
and feces.
The extraction recovery of Rs-1 and IS in plasma, urine and feces
at 4 QC concentrations ranged 70.7%–90.4% and 83.1%–94.7%, and
the matrix effect of Rs-1 and IS ranged 85.8%–100.4% and 78.1%–
100.0%, respectively. Results are presented in Table 2 and indicate
that the extraction and puriﬁcation method in this study is suitable
and reliable for Rs-1 and IS in plasma, urine and feces.
The stability of Rs-1 was investigated under a variety of
conditions at 4 QC concentration levels and the results were
summarized in Table 3. The QC samples were stable in all
matrices at room temperature (2573 1C) for 24 h and the RE%
was –9.9% to 10.7%. Rs-1 was also considered to be stable afterFigure 3 Representative MRM chromatograms of (A) blank rat plasma
proﬁles 10 min after injection administration of Rs-1.three freeze–thaw cycles (RE%, –6.7% to 3.3%). Long-term
stability was stable for 20 days at 80 1C (RE%, –7.5% to
3.7%) and the ready-to-inject sample placed in autosampler at
25 1C for 24 h was also stable (RE%, –2.3% to 3.5%). All the
results showed that Rs-1 was stable under those different condi-
tions without any signiﬁcant degradation.
The precision and accuracy of the dilution experiments were
evaluated as well and they all met the requirement. After incubation
with β-glucuronidase or sulfatase, the determination of Rs-1 in
plasma and urine was within the acceptable range as detailed in
Table 4. The results proved that incubation with β-glucuronidase or
sulfatase at 37 1C for the established time had no impact on the
determination of Rs-1.
3.5. Application of analytical method
3.5.1. Pharmacokinetics of Rs-1
After a single oral administration of 70 mg/kg or a single
intravenous injection of 1.37 mg/kg Rs-1 to rats (n¼6), Rs-1
could be conjugated with glucuronic acid or sulfate. Rs-1
glucuronide and sulfate conjugates were characterized by the
deprotonated molecular ion [MH] at m/z 629.1 and 533.2,
which were 176 and 80 more than Rs-1 (m/z 453.2), respectively.
The Rs-1 fragment was observed at m/z 453.2 in product ion mass
spectra of Rs-1 glucuronide and sulfate conjugates (Fig. 6). The
peak area of Rs-1 was enhanced after enzymolysis of the samples
with β-glucuronidase or sulfatase, which indicated that it contains
Rs-1 glucuronide and sulfate conjugates. The mean plasma
concentration versus time proﬁles of Rs-1 and its conjugates
(n¼6 for each time point) are illustrated in Fig. 7, and the major
pharmacokinetic parameters from non-compartment model analy-
sis are presented in Table 5.
The proﬁle revealed that after intravenous injection the elimina-
tion of Rs-1 and its two metabolites was very rapid, and the
unmodiﬁed Rs-1 was the main compound. Rs-1 glucuronide and
sulfate conjugates reached peak concentration at 5 min. At 10 min,
Rs-1 glucuronide concentration (679.57150.7 ng/mL) was higher
than that of the parent compound (378.37178.4 ng/mL) and Rs-1, (B) rat plasma spiked with Rs-1 at LLOQ, and (C) Rs-1 in plasma
Figure 4 Representative MRM chromatograms of (A) blank rat urine, (B) rat urine spiked with Rs-1 at LLOQ, and (C) Rs-1 in urine proﬁles
12–24 h after oral administration of Rs-1.
Figure 5 Representative MRM chromatograms of (A) blank rat feces, (B) rat feces spiked with Rs-1 at LLOQ, and (C) Rs-1 in feces proﬁles
12–24 h after oral administration of Rs-1.
Ping Mao et al.248sulfate (285.27125.8 ng/mL). Rs-1 sulfate conjugate was cleared
the fastest from the bloodstream since only trace amounts of
Rs-1 sulfate (below the LLOQ) could be detected at 45 min,
while at this time point the concentration of Rs-1 was
57.1719.7 ng/mL and Rs-1 glucuronide was 55.7736.1 ng/mL.
Rs-1 glucuronide and Rs-1 were still present in plasma at 12 and
24 h, respectively.
After oral administration of Rs-1 it was metabolized rapidly and
Rs-1 glucuronide was the main compound, followed by Rs-1
sulfate. The mean AUC0–t of Rs-1, its glucuronide and sulfate
conjugates were 1162.07200.6, 16,924.377944.0, and
2822.87967.9 mgUh/L, respectively. The time-to-peak concentra-
tion (Tmax) of Rs-1 and its sulfate conjugate were observed at
about 1.7 h, and Rs-1 glucuronide had a slight delay at about 2.0 h.
The apparent volume of distribution (V) value suggested that Rs-1,Rs-1 glucuronide and sulfate could extensively distribute into
organs and tissues. Comparing the clearance and t1/2 values of
Rs-1, Rs-1 glucuronide and sulfate, Rs-1 could be most quickly
eliminated from the circulatory system. The absolute oral bioavail-
ability of Rs-1 was 2.3%, and the total absorption rose to 31.5% in
addition to its glucuronide and sulfate metabolites. It could be
observed from the concentration-time curve that there were double
peaks (approximately at 4.5–6 h) of Rs-1 (Fig. 7), and that was the
same as obtained previously with resveratrol. The most popular
explanation for the double peaks was enterohepatic circulation.
The resveratrol glucuronide could be deconjugated in the gut to the
active compound, resveratrol, by bacterial glucuronidases and then
reabsorbed14,24. Those results revealed that Rs-1 was poorly
bioavailable, which might be in part due to the low absorption
and extensive metabolism.
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Urine and feces were collected at different exposure times after
oral administration of 70 mg/kg Rs-1. Rs-1 glucuronide and sulfate
conjugates were also detected in the urine samples by MS/MS, and
the peak area of Rs-1 was also enhanced after the enzymolysis of
the samples with β-glucuronidase or sulfatase. While in feces, only
unchanged Rs-1 was detected, and the peak area of Rs-1 showed
no enhancement after the enzymolysis with β-glucuronidase or
sulfatase. As shown in Fig. 8, 60.3% of the gavaged dose of Rs-1
was excreted via the feces in unchanged form over 60 h after oral
gavage. The major duration of excretion of Rs-1 in feces was
8–24 h and 60% of the gavage dose was detected in this period.
With the decreasing Rs-1 concentration in the rat, the excretion
ratio was reduced and accounted for only 0.3% during the 24–60 h
period; 0.09% was excreted through the urine 60 h after oral
gavage. The major forms of Rs-1 in urine were Rs-1 glucuronide
and sulfate, which were 0.047% and 0.042% of the gavaged dose,
and Rs-1 was slightly less than 0.003%. 8–24 h was also the main
period of excretion in urine and decreased with time. The data
showed that Rs-1 was mainly excreted via the feces in unchangedTable 1 Intra- and inter-day precision and accuracy of Rs-1 in rat p














Table 2 Recovery and matrix effects of Rs-1 and IS in rat plasma,















Feces 200form after oral gavage, and most appeared to be unabsorbed
according to the drug concentration in plasma.
Viniferins (resveratrol oligomers) are found in wine and some
popular herbal medicines, and have been linked to many health-
promoting properties in humans. Rs-1 is an important kind of
viniferin, and its pharmacological activities have been widely
studied. Its pharmacokinetics show poor water solubility and high
metabolism, especially after oral administration. As with resvera-
trol, in order to improve the poor oral bioavailability, increase the
solubility, and protect it from being metabolized, structural
modiﬁcation to the phenolic hydroxyl, such as methylation25,26
and acetylation27, should be considered in future studies. More-
over, this formulation research is also needed to increase the
absorption.4. Conclusions
In summary, a rapid and sensitive LC–MS/MS method for the
determination of Rs-1 in rat plasma, urine and feces was developedlasma, urine and feces (n¼5).
Inter-day













urine and feces (n¼5).
Recovery Matrix effect
Mean (%) RSD (%) Mean (%) RSD (%)
90.4 12.3 92.9 13.4
86.4 5.2 90.1 8.3
86.4 1.9 95.9 4.6
82.0 3.9 85.8 2.1
87.6 3.9 97.3 1.4
80.0 6.7 96.9 1.7
77.1 5.5 98.4 2.2
70.7 1.3 91.9 1.8
88.1 3.4 98.8 3.2
89.7 0.7 100.4 0.8
82.6 2.7 97.4 1.6
88.6 1.1 99.0 2.9
83.1 9.3 78.1 10.0
94.7 3.2 100.0 2.4
85.5 1.1 84.5 1.7





















Plasma 1.42 –0.7 1.8 0.7 5.8 0.3 8.2 –2.3 4.9
3.56 –9.9 1.9 –2.2 7.4 –0.4 2.9 –2.1 4.4
347.5 –3.9 7.0 –1.0 5.9 –0.4 5.6 1.5 4.1
1737 –0.9 5.9 3.3 5.2 0.4 0.9 0.1 6.0
Urine 1.42 10.7 4.1 –4.5 9.3 –3.0 4.3 –0.1 6.8
3.56 6.4 1.7 0.8 1.8 3.7 6.2 –0.7 3.0
347.5 4.5 3.1 –6.5 2.9 –4.0 2.1 3.5 1.3
1737 –0.6 0.9 –6.7 1.5 –7.5 1.4 –1.4 1.8
Feces 1.42 7.6 4.4 –0.7 3.4 2.1 4.6 0.9 3.7
3.56 –4.0 7.5 0.0 2.6 –1.5 5.0 0.5 2.7
347.5 –0.3 1.7 –0.8 2.7 –0.2 1.8 –0.6 4.2
1737 0.0 9.5 –2.1 6.0 –1.0 2.4 –0.4 8.5
Table 4 Effect of β-glucuronidase and sulfatase to Rs-1 in plasma and urine (n¼5).
Matrix Nominal concentration (ng/mL) β-Glucuronidase Sulfatase
Accuracy (RE, %) Precision (RSD, %) Accuracy (RE, %) Precision (RSD, %)
Plasma 1.42 4.1 3.7 2.0 3.5
3.56 –6.5 3.9 –3.0 5.1
347.5 –6.1 2.5 –2.1 2.6
1737 0.7 2.3 3.8 2.6
Urine 1.42 4.8 3.7 5.6 3.1
3.56 1.6 7.0 3.0 4.1
347.5 –0.6 2.5 –1.4 1.5
1737 –4.2 2.4 –4.8 2.5
Figure 6 Product ion spectra (MS/MS) of (A) Rs-1 glucuronide and (B) Rs-1 sulfate metabolites.
Ping Mao et al.250and validated, and the method was successfully applied to determine
the bioavailability, metabolism and excretion of Rs-1 in rats. To the
best of our knowledge, this is the ﬁrst paper to report the metabolism
and excretion of Rs-1. Moreover, the method of Rs-1 measurement in
plasma in this study had a shorter sample turnover rate of 4 min per
sample and higher sensitivity with LLOQ of 1.42 ng/mL comparedwith a previous study21. The absolute oral bioavailability of Rs-1 was
2.3%, and the total absorption rose to 31.5% with addition of its
glucuronide and sulfate metabolites. 60.3% of the gavaged dose of Rs-
1 was excreted via the feces in unchanged form after oral gavage. The
results indicate that both poor absorption and extensive metabolism are
important factors leading to the poor bioavailability of Rs-1, which can
Figure 7 The mean plasma concentration–time proﬁle in rats after (A) oral administration of 70 mg/kg Rs-1 and (B) intravenous administration
of 1.37 mg/kg Rs-1 (n¼6).
Table 5 Non-compartmental pharmacokinetics parameters of Rs-1, Rs-1 glucuronide and Rs-1 glucuronide after a single oral or
intravenous administration in rat plasma.
Parameter Unit Oral (70 mg/kg, n¼6) Intravenous (1.37 mg/kg, n¼6)
Rs-1 Rs-1 glucuronide Rs-1 sulfate Rs-1 Rs-1 glucuronide Rs-1 sulfate
AUC0–t mg U h/L 1,162.07200.6 16,924.377944.0 2,822.87967.9 1,004.77209.9 299.005764.9 96.2734.1
AUC(0–1) mg U h/L 1,181.97193.9 18,758.379293.0 3,303.27992.6 1,017.67206.3 299.006764.9 96.2734.1
MRT(0–t) h 5.670.6 7.471.5 7.470.9 1.570.2 2.0271.4 0.470.3
MRT(0–1) h 6.070.6 9.772.5 12.374.6 2.070.4 2.0271.4 0.470.3
t1/2z h 4.271.6 7.371.8 9.574.8 5.871.6 1.170.5 0.370.2
Tmax h 1.770.2 2.070.7 1.770.2 0.0370.00 0.1070.04 0.0970.05
Vz/F L/kg 379.77180.4 45.1715.6 298.17144.0 12.275.8 6.672.6 5.473.0
CLz/F L/h/kg 60.6710.1 4.471.8 23.8711.0 1.470.3 4.771.1 16.578.6
Cmax mg/L 399.0797.8 2,984.77745.7 714.87176.1 7,611.771,510.5 1,258.37389.4 488.87172.0
F (%) – 2.3 – – – – –
–Not applicable.
Figure 8 (A) Urinary and (B) fecal cumulative excretion proﬁle of Rs-1 in rats after single oral dose of 70 mg/kg Rs-1 (n¼6).
Pharmacokinetics of δ-viniferin in rats by LC–ESI-MS/MS 251provide a basis for further studies on structural modiﬁcation and dosage
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